Back to Search
Start Over
Exelixis initiates STELLAR-305 phase 2/3 pivotal trial of zanzalintinib in combo with pembrolizumab in patients with previously untreated recurrent or metastatic SCCHN
- Source :
- PharmaBiz. December 6, 2023
- Publication Year :
- 2023
-
Abstract
- Exelixis, Inc. announced the initiation of STELLAR-305, a phase 2/3 pivotal trial evaluating zanzalintinib in combination with pembrolizumab versus pembrolizumab alone in patients with previously untreated PD-L1-positive recurrent or metastatic [...]
- Subjects :
- Exelixis Inc. -- Product development
Care and treatment
Product development
Cabozantinib
Recurrence (Disease) -- Care and treatment
Chemotherapy
Tyrosine -- Product development
Squamous cell carcinoma -- Care and treatment
Pembrolizumab
Cancer metastasis -- Care and treatment
Metastasis -- Care and treatment
Diseases -- Relapse
Cancer -- Chemotherapy
Subjects
Details
- Language :
- English
- Database :
- Gale General OneFile
- Journal :
- PharmaBiz
- Publication Type :
- Periodical
- Accession number :
- edsgcl.775579542